D. Samba Reddy, PhD, RPh

D. Samba Reddy, PhD, RPh


Department of Neuroscience and Experimental Therapeutics
8447 Riverside Pkwy
2008 Medical Research and Education Building
Bryan, TX   77807-3260

Phone: 979.436.0324


  • PhD, Pharmacology, Panjab University Chandigarh (1998)
  • RPh, Pharmacy, Texas State BOP, Austin, Texas.
  • Postdoctoral, National Institutes of Health, Bethesda, Maryland

Professional Honors

  • Fellow, American Epilepsy Society (AES)
  • Fellow, American Association for the Advancement of Science 
  • Fellow, American Association of Pharmaceutical Scientists
  • SAB Member, Environmental Protection Agency (EPA)
  • Contributing Editor, Epilepsy Currents (AES Journal)
  • Chartered Member, NIH Study Section ANIE & CNNT 
  • Editor-in-Chief, Int J Pharm Sci Nanotechnology 
  • Review Editor, Frontiers in Neuroscience; Pharmacology
  • Delegate Member, The United States Pharmacopoeia (USP)
  • Registered Pharmacy Practitioner, Texas, United States
  • Texas A&M Medicine Excellence in Research Award (2015)

Research Interests

Molecular Pathophysiology and Neurotherapeutics of Epilepsy and Brain Disorders

Dr. Reddy has been in the pharmacology research field for over 24 years.  His lab is mainly focused on drug development for epilepsy and brain disorders. Epilepsy and seizure disorders affect about 60 million people worldwide, including thousands of veterans and civilians in the United States. He directs a productive multidisciplinary group utilizing pharmacological, electrophysiological, histological, mass spectrometric, and transgenic techniques. Current projects in the Reddy lab are centered on elucidating the molecular pathophysiology of, and developing mechanism-based novel drug therapies for, epileptogenesis, status epilepticus, post-traumatic epilepsy, post-stroke epilepsy, and chemical neurotoxicity. He has a long standing interest in neurosteroids as novel anticonvulsants. Dr. Reddy was instrumental in discovering many preclinical models, mechanism-based treatment strategies, and novel medicines for complex brain disorders. His lab has been conducting pioneering investigations on neurosteroid interactions at synaptic and extrasynaptic GABA-A receptors. His research has been continuously funded by the NIH for over 14 years. He is the principal investigator of an NIH Cooperative Agreement U01 project focusing on novel treatments for organophosphate and chemical nerve agent intoxication. He directs a DOD project on post-traumatic epilepsy after traumatic brain injury, which affects many soldiers who have been in combat. He teaches both medical and graduate courses on human pharmacology and neurology and mentors many undergraduates and doctoral & postdoctoral trainees. Dr. Reddy has published over 180 papers and book-chapters (h-index 46; i-index 86), which are available worldwide (http://orcid.org/0000-0003-2735-9550).

Selected Publications

  • Reddy DS, Yoshimurab RF, Ramanathan G, Carver CM, Johnstone TB, Hogenkamp DJ, and Gee KW (2018). Role of β2/3-specific GABA-A receptor isoforms in the development of hippocampus kindling epileptogenesis. Epilepsy & Behavior, 82: 57-63. 
  • Reddy DS, Wu X, Golub VM, and Dashwood WM. Dashwood RH (2018). Screening of Histone Deacetylase Activity Inhibitors. Current Protocols in Pharmacology, e41, Volume 81: 1-14. 
  • Chuang S-H and Reddy DS (2018). 3β-Methyl-neurosteroid analogs are preferential positive allosteric modulators and direct activators of extrasynaptic GABA-A receptors in the hippocampus dentate gyrus subfield. J Pharmacol Exp Therap, 365: 1-19. 
  • Kuruba R, Wu X and Reddy DS (2018). Benzodiazepine-refractory status epilepticus, neuroinflammation, and neurodegeneration after acute organophosphate intoxication. Biochim Biophys Acta (MS).
  • Wu X, Kuruba R and Reddy DS (2018). Midazolam-resistant seizures and neuronal injury following acute intoxication with diisopropylfluorophosphate, an organophosphate pesticide and surrogate for nerve agents. J Pharmacol Exp Therap (MS).
  • Chuang S-H and Reddy DS (2018). Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain: Therapeutic insights for epilepsy. J Pharmacol Exp Therap 364:180-197.
  • Reddy SD, Clossen B and Reddy DS (2018). Epigenetic histone deacetylation inhibition prevents the development and persistence of temporal lobe epilepsy. J Pharmacol Exp Therap 364:97-109.
  • Reddy DS (2018). Drug Therapy for the Management of ADHD (Chapter 18). In: Brody’s Human Pharmacology, 6th Edition (Eds. Lynn Wecker et al,), Elsevier, pp-18-2, 18-7.
  • Reddy DS (2018). Drug Therapy for Migraine Headache (Chapter 31). In: Brody’s Human Pharmacology, 6th Edition (Eds. Lynn Wecker et al,), Elsevier, pp-31-2, 31-7.
  • Reddy DS (2017). Sex differences in the anticonvulsant neurosteroids. J Neurosci Res 95:661-670.
  • Reddy DS, Gangisetty O and Wu X (2017). PR-Independent neurosteroid regulation of alpha-2-GABA-A receptor plasticity in the hippocampus subfields. Brain Res 1659: 142–147.
  • Reddy DS and Colman E (2017). A comparative analysis of human organophosphate poisonings using social media. Clin Transl Sci 10(3):225-230.
  • Reddy DS (2017). Do oral contraceptives increase epileptic seizures? Expert Rev Neurotherapeutics 17(2):129-134.
  • Clossen BL and Reddy DS (2017). Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochim Biophys Acta 1863(6):1519-1538.
  • Younus I and Reddy DS (2017). Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy. Pharmacology & Therapeutics 177: 108-122.
  • Clossen BL and Reddy DS (2017). Catamenial-like seizure exacerbation in mice lacking extrasynaptic GABA-A receptors. J Neurosci Res, 95:1906-1916.
  • Wu X, Muthuchamy M and Reddy DS (2017). Atomic force microscopy investigations of fibronectin and α5β1-integrin signaling in neuroplasticity and seizure susceptibility in experimental epilepsy. Epilepsy Res 138: 71-80.
  • Reddy DS (2017). Perimenstrual seizures and neurosteroid withdrawal (Chapter 63). In: Models of Seizure and Epilepsy, 2nd edition (Eds. Pitkanen A, Buckmaster P, Galanopoulou A, Moshe SM), Elsevier Press); pp-933-940.
  • Younus Y and Reddy DS (2017). A Resurging boom in new drugs for epilepsy and brain disorders. Exp Rev Clin Pharmacol 11(1):27-45.
  • Reddy DS (2017). Clinical pharmacology of modern antiepileptic drugs. Int J Pharma Sci Nanotech 10(6): 3875-3890.
  • Reddy DS and Volkmer II R (2017). Neurocysticercosis as an infectious acquired epilepsy worldwide. Seizure: Eur J Epilepsy 52:176-181.
  • Reddy DS (2016). Catamenial epilepsy: discovery of an extrasynaptic molecular mechanism for targeted therapy. Front Cell Neurosci 10(101): 1- 14.
  • Younus I and Reddy DS (2016). Seizure facilitating activity of the oral contraceptive ethinyl estradiol. Epilepsy Res 121:29-32.
  • Carver CM and Reddy DS (2016). Neurosteroid structure-activity relationships for functional activation of extrasynaptic GABA-A receptors in the hippocampus. J Pharmacol Exp Therap 357:188–204.
  • Carver CM, Chuang S-H and Reddy DS (2016). Zinc selectively inhibits the neurosteroid-sensitive, extrasynaptic-GABA-A receptors in the hippocampus. J Neurosci 36(31): 8070–8077.
  • Reddy DS and Golub VM (2016). The pharmacological basis of cannabis use for epilepsy. J Pharmacol Exp Therap 357:45–55.
  • Reddy DS and Estes W (2016). Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci 37(7): 543-561.
  • Reddy DS (2016). Neurosteroids for the potential protection of humans against organophosphate toxicity. Ann NY Acad Sci 1378(1):25-32.
  • Xin W, Muthuchamy M and Reddy DS (2016). Application of atomic force microscopy protocol for measurement of membrane plasticity and extracellular interactions in single neurons in epilepsy. Front Ageing Neurosci 8(88):1-19.
  • Reddy DS (2016). The neuroendocrine basis of sex differences in epilepsy. Pharmacol Biochem Behav 152:97-104.
  • Reddy DS, Bhimani A, Kuruba R, Park MJ and Sohrabji F (2016). Prospects of modeling post-stroke epileptogenesis. J Neurosci Res 95:1000-1016.
  • Reddy DS, Clossen B and Medi H (2016). Cellular and molecular mechanisms of neuroinflammation in epilepsy. Int J Pharm Sci Nanotech 9(4): 3331-3336.
  • Reddy DS (2016). The utility of cannabidiol in the treatment of refractory epilepsy. Clin Pharmacol Therap 17(2): 129–134.
  • Reddy SD, Younus I, Clossen B and Reddy DS (2015). Antiseizure activity of midazolam in mice lacking delta-subunit extrasynaptic GABA-A receptors. J Pharmacol Exp Therap 353:517–528.
  • Reddy SD and Reddy DS (2015). Midazolam as an anticonvulsant antidote for organophosphate intoxication: A pharmacotherapeutic appraisal. Epilepsia 56(6):813–821.
  • Golub VM, Brewer J, Wu X, Kuruba R, Short J, Manchi M, Swonke M, Younus Y and Reddy DS (2015). Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration. Front Aging Neurosci 7:196.